Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein

M.G. Scott, A.C.E. Vreugdenhil, W.A. Buurman, R.E. Hancock*, M.R. Gold

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We investigated the mechanism by which cationic antimicrobial peptides block the activation of macrophages by LPS. The initial step in LPS signaling is the transfer of LPS to CD14 by LPS binding protein (LBP), Because many cationic antimicrobial peptides bind LPS, me asked whether these peptides block the binding of LPS to LBP. Using an assay that measures the binding of LPS to immobilized LBP, we show for the first time that a variety of structurally diverse cationic antimicrobial peptides block the interaction of LPS with LBP. The relative ability of different cationic peptides to block the binding of LPS to LBP correlated with their ability to block LPS-induced TNF-alpha production by the RAW 264.7 macrophage cell line.
Original languageEnglish
Pages (from-to)549-553
Number of pages5
JournalJournal of Immunology
Volume164
DOIs
Publication statusPublished - 1 Jan 2000

Fingerprint

Dive into the research topics of 'Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein'. Together they form a unique fingerprint.

Cite this